An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Acerta Pharma
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Results of population pharmakoinetics of Acalabrutinib and its Active Metabolite using data from this and other 12 studies, published in the Clinical Pharmacokinetics
- 02 Mar 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2018.